AMM:DADI's PB Ratio is ranked better than 83.06% of 921
companies
in the Drug Manufacturers industry
Industry Median: 1.91
vs AMM:DADI: 0.81
During the past 12 months, Dar Al Dawa Development and Investment's average Book Value Per Share Growth Rate was 6.10% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 8.20% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 4.90% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -3.60% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Dar Al Dawa Development and Investment was 9.60% per year. The lowest was -25.50% per year. And the median was 0.30% per year.
Back to Basics: PB Ratio
Dar Al Dawa Development and Investment (AMM:DADI) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Dar Al Dawa Development and Investment PB Ratio Related Terms
Dar Al Dawa Development and Investment PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dar Al Dawa Development and Investment PB Ratio Chart
Dar Al Dawa Development and Investment Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Dar Al Dawa Development and Investment's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dar Al Dawa Development and Investment PB Ratio vs Drug Manufacturers Industry
Dar Al Dawa Development and Investment PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Dar Al Dawa Development and Investment (AMM:DADI) has a PB Ratio of 0.81 as of Jul. 02, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Dar Al Dawa Development and Investment and its competitors. This is 14% below median its historical median of 0.94. Over the past decade, Dar Al Dawa Development and Investment's PB Ratio has ranged from 0.56 to 1.62. According to the industry distribution chart, Dar Al Dawa Development and Investment ranks #156 out of 921 companies in the Drug Manufacturers industry, placing it in the top 16.9%.
Is Dar Al Dawa Development and Investment's PB Ratio too high?
Dar Al Dawa Development and Investment's current PB Ratio of 0.81 is 14% below median its 10-year median of 0.94. Over the past 10 years, this metric has ranged from a low of 0.56 to a high of 1.62. The Drug Manufacturers industry median PB Ratio is 1.91. Dar Al Dawa Development and Investment's value of 0.81 is 57.6% below this industry median. Based on the distribution chart, Dar Al Dawa Development and Investment ranks #156 out of 921 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Dar Al Dawa Development and Investment has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Dar Al Dawa Development and Investment's PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Dar Al Dawa Development and Investment ranks #156 out of 921 companies for PB Ratio. This places Dar Al Dawa Development and Investment in the top 17% of its industry — outperforming the majority of peers. The industry median PB Ratio is 1.91. Dar Al Dawa Development and Investment's value of 0.81 is 57.6% below this benchmark. Historically, Dar Al Dawa Development and Investment's own PB Ratio has ranged from 0.56 to 1.62 over the past decade. While the company's 10-year median is 0.94 vs. the industry median of 1.91, Dar Al Dawa Development and Investment has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.91, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dar Al Dawa Development and Investment's current PB Ratio of 0.81 is 57.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Dar Al Dawa Development and Investment and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dar Al Dawa Development and Investment's current PB Ratio is 0.81, which is 14% below median its own 10-year median of 0.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dar Al Dawa Development and Investment stock overvalued right now?
Based on GuruFocus' analysis, Dar Al Dawa Development and Investment (AMM:DADI) is currently considered Fairly Valued. The stock's GF Value™ is JOD1.10, compared to a current price of JOD1.14 — trading 3.6% above its estimated fair value. The current PB Ratio is 0.81, which is 14% below median its 10-year median of 0.94 and 57.6% below the Drug Manufacturers industry median of 1.91. Dar Al Dawa Development and Investment's overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Dar Al Dawa Development and Investment (AMM:DADI), the current PB Ratio is 0.81 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dar Al Dawa Development and Investment (AMM:DADI) Overvalued in 2026?
Based on GuruFocus' analysis, Dar Al Dawa Development and Investment stock appears to be overvalued.
The current stock price of JOD1.14 is trading 3.6% above its estimated GF Value™ of JOD1.10.
GuruFocus considers Dar Al Dawa Development and Investment to be Fairly Valued.
Key valuation signals for AMM:DADI:
PB Ratio: 0.81 (14% below median its 10-year median of 0.94)
GF Value™: JOD1.10 vs. price of JOD1.14 (3.6% above fair value)
Industry Position: 57.6% below the Drug Manufacturers median (#156 of 921)
No single metric tells the full story. See the AMM:DADI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dar Al Dawa Development and Investment Business Description
Dar Al Dawa Development and Investment is a pharmaceutical company. The main objectives are the production of medical, chemical, and pharmaceutical products, and importing pharmaceutical products. The subsidiaries' main objectives are marketing and distributing the Company's products, producing some specialized medical products, and investment activities. It offers products in the therapeutic areas of anti-infective, cardiovascular, diabetes, dermatology, eye-ear preparations, gastroenterology and metabolism, genitourinary system and sex hormones, musculoskeletal system, nervous system, ophthalmological/otological, and respiratory system, as well as vitamins. The company's geographical segments are Levant and Iraq, Gulf and Yemen, Africa, and Europe and Asia.
77GF Score
Get the complete analysis for AMM:DADI
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMM:DADI has been successfully added to your 
